TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

TEVA$42.61+2.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated statements of changes in equity

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at June 30, 2024	1,239	58	27,829	(14,519)	(2,881)	(4,128)	6,359	204	6,563
Net Income (loss)				(437)			(437)	47	(390)
Other comprehensive income (loss)					113		113	67	180
Issuance of Shares	1	*	*				*		*
Stock-based compensation expense			29				29		29
Balance at September 30, 2024	1,240	$58	$27,860	$(14,956)	$(2,769)	$(4,128)	$6,065	$319	$6,383

*	Represents an amount less than 0.5 million.

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2023	1,227	57	27,807	(13,534)	(2,697)	(4,128)	7,506	620	8,126
Net Income (loss)				(1,422)			(1,422)	(262)	(1,684)
Other comprehensive income (loss)					(69)		(69)	(6)	(75)
Issuance of Shares	13	1	*				1		1
Stock-based compensation expense			89				89	—	89
Proceeds from exercise of options			7				7		7
Dividend to non-controlling interests**								(18)	(18)
Purchase of shares from non-controlling interests***			(45)		(3)		(48)	(16)	(64)
Balance at September 30, 2024	1,240	$58	$27,860	$(14,956)	$(2,769)	$(4,128)	$6,065	$319	$6,383

*	Represents an amount less than $0.5 million.

**	In connection with dividends to non-controlling interests in Teva’s joint venture in Japan.

***	Purchase of shares from non-controlling interests in a Teva’s subsidiary in Switzerland.

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at June 30, 2023 **	1,227	57	27,748	(14,066)	(2,677)	(4,128)	6,936	656	7,592
Net Income (loss)**				69			69	8	77
Other comprehensive income (loss)					(233)		(233)	(16)	(249)
Issuance of shares			*				*		*
Stock-based compensation expense			31				31		31
Dividend to non-controlling interest ***								(67)	(67)
Balance at September 30, 2023 **	1,227	$57	$27,780	$(13,995)	$(2,910)	$(4,128)	$6,804	$582	$7,387

*	Represents an amount less than $0.5 million.

**	The data presented for prior periods has been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. For additional information, see note 1c.

***	In connection with a declaration on dividend to non-controlling interest in Teva’s joint venture in Japan.

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive (loss)	Treasury shares	Total Teva shareholders’ equity	Non-controlling interests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2022 **	1,217	57	27,688	(12,975)	(2,838)	(4,128)	7,804	794	8,598
Net Income (loss)				(1,022)			(1,022)	(60)	(1,082)
Other comprehensive income (loss)					(72)		(72)	(84)	(156)
Issuance of Shares	10	*	*				*		*
Stock-based compensation expense			93				93	—	93
Dividend to non-controlling interest ***								(67)	(67)
Balance at September 30, 2023 **	1,227	$57	$27,780	$(13,995)	$(2,910)	$(4,128)	$6,804	$582	$7,387

*	Represents an amount less than $0.5 million.

**	The data presented for prior periods has been revised to reflect a revision in relation to a contingent consideration liability and related expenses in the consolidated financial statements. For additional information, see note 1c.

***	In connection with a declaration on dividend to non-controlling interest in Teva’s joint venture in Japan.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.